Introduction/Background Vulvar carcinoma (VC) is a rare malignancy with an incidence rate of 3–5% of all gynaecological malignancies. Information regarding prognostic factors for disease-free and overall survival in vulvar cancer is limited. We present our institute’s retrospective collected data.

Aims -To analyze the prognostic factors and survival outcomes related to the recurrence of vulvar cancer.

Methodology Retrieved the information regarding patients‘ clinical details and treatment given from the case records of all the vulvar cancer patients

Treated during the year 2010–2018 at tertiary Cancer centre,

Results A total of 72 case records were retrieved for this retrospective analysis. Median age was 63 years. 25% (n=18) was recurrence rate. Median time of recurrence is 8 months (IQR= 14.25 months), <2yrs- 84% recurrences, >2yrs 16% recurrences. Most common site vulva ( 44%,) n= 11, followed by inguinal node (28%) n=7, Distant metastases (%) n=1. 3 year OS after recurrence is 6.67%. The present study suggests that the stage at presentation (advanced stage), lymph node positivity, LVSI positive, ECE positive, not received adjuvant therapy are prognostic predictors of recur

Conclusion The treatment of carcinoma vulva should be individualized with multidisciplinary approach.

Further studies are needed to elucidate the molecular background, that could help to stratify patients for surgical planning, adjuvant therapy and intensified follow-up to prevent recurrences

Disclosures No.